

IN THE CLAIMS:

Please cancel claims 6 and 24, and amend claims 1, 2, 4, 5, 7, and 23. Please add claims 25-31.

This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

1. (Currently Amended): A method for identifying a ~~eandidate~~ compound capable of treating urinary incontinence~~a urological disorder~~, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:104; and

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:103;

under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the ~~test~~ compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

thereby identifying a compound capable of treating urinary incontinence~~a urological disorder~~.

2. (Currently Amended): The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide ~~and~~ an antibody.

3. (Previously Presented): The method of claim 1, wherein the polypeptide further comprises heterologous sequences.

4. (Currently Amended): The method of claim 1, wherein the sample comprises ~~thean isolated~~ polypeptide, a membrane-bound form of ~~thean isolated~~ polypeptide or a cell comprising the polypeptide.

5. (Currently Amended): The method of claim 4, wherein the cell is selected from the group consisting of a bladder cell, a prostate cell, a kidney cell, a vascular cell, a urethral cell, a dorsal root ganglion cell, a trigeminal ganglion cell, a brain cell, and a spinal cord cell~~a urological cell~~.

6. (Canceled)

7. (Currently Amended): The method of claim 1, wherein the binding of the ~~test~~ compound to the polypeptide is detected by a method selected from the group consisting of:

a) a competition binding assay;

- b) an immunoassay; and
- c) a yeast two-hybrid assay.

8-22. (Canceled)

23. (Currently Amended): The method of claim 1, wherein binding of the test compound to the polypeptide is detected by an assay for an activity of the polypeptide selected from the group consisting of:

- a) a carboxypeptidase assay; and
- b) an assay for measuring proteolysis of extracellular peptides or proteins.

24. (Canceled):

25. (New): A method for identifying a compound capable of treating benign prostatic hyperplasia, comprising:

a) combining a compound to be tested with a sample comprising a polypeptide selected from the group consisting of:

- i) a polypeptide comprising the amino acid sequence of SEQ ID NO:104; and
- ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:103;

under conditions suitable for binding of the compound to the polypeptide; and

b) detecting binding of the compound to the polypeptide to thereby identify a compound which binds to the polypeptide;

thereby identifying a compound capable of treating benign prostatic hyperplasia.

26. (New): The method of claim 25, wherein the compound is selected from the group consisting of a small molecule, a peptide and an antibody.

27. (New): The method of claim 25, wherein the polypeptide further comprises heterologous sequences.

28. (New): The method of claim 25, wherein the sample comprises the polypeptide, a membrane-bound form of the polypeptide or a cell comprising the polypeptide.

29. (New): The method of claim 28, wherein the cell is selected from the group consisting of a bladder cell, a prostate cell, a kidney cell, a vascular cell, a urethral cell, a dorsal root ganglion cell, a trigeminal ganglion cell, a brain cell, and a spinal cord cell.

30. (New): The method of claim 25, wherein binding of the compound to the polypeptide is detected by a method selected from the group consisting of:

- a) a competition binding assay;
- b) an immunoassay; and
- c) a yeast two-hybrid assay.

31. (New): The method of claim 25, wherein binding of the compound to the polypeptide is detected by an assay for an activity of the polypeptide selected from the group consisting of:

- a) a carboxypeptidase assay; and
- b) an assay for measuring proteolysis of extracellular peptides or proteins.